Veracyte, Inc. VCYT
Set alert
50.01 USD -2.16 -4.14%
At close · Oct 30
50.01 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
49.65 Day range 51.93
30.01 52-week range 60.49
- YTD
- +18.79%
- 1 year
- +41.55%
- Open
- 51.54
- Prev close
- 52.17
- Mkt cap
- 4.02B
- Vol
- 1.02M
- Avg vol
- 1.39M
- EPS
- 1.40
- P/E
- 35.72
- Div yield
- 0.00%
More statistics
- Low
- 49.65
- High
- 51.93
- Forward P/E
- 25.74
- Beta
- 1.95
- Short ratio
- 6.64
- Inst. own
- 115.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 44.26
- 200-d avg
- 42.78
- 1y target
- 59.73
2Y chart
Events in this range
- Aug 6, 2025Earnings: 0.44; estimate 0.31; surprise 41.94%
- Nov 4, 2025Earnings: 0.51; estimate 0.32; surprise 59.38%
- Feb 25, 2026Earnings: 0.53; estimate 0.4083; surprise 29.81%
- May 5, 2026Earnings: 0.52; estimate 0.34; surprise 52.94%
- Jul 30, 2026Earnings: 0.54; estimate 0.4103; surprise 31.61%
- Aug 3, 2026Rating: Canaccord Genuity · Hold → Hold
- Aug 4, 2026Rating: Morgan Stanley · Underweight → Underweight
- Aug 4, 2026Rating: Stephens & Co. · Overweight → Overweight
- Aug 4, 2026Rating: Piper Sandler · Overweight → Overweight
- Sep 9, 2026Rating: UBS · Buy → Buy
- Sep 15, 2026Rating: Freedom Capital Markets · Buy → Buy
Signals (97)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| RSI: Oversold | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| RSI: Overbought | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| RSI: Overbought | Jun 1, 2026 | 5 months ago |
| RSI: Overbought | May 27, 2026 | 5 months ago |
| RSI: Overbought | May 20, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| RSI: Overbought | May 6, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 30, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 18, 2026 | 7 months ago |
| RSI: Oversold | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 6, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 18, 2026 | 8 months ago |
| RSI: Oversold | Feb 4, 2026 | 9 months ago |
| SMA: Bearish | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 14, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 9, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 9, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 5, 2025 | 11 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 5, 2025 | 12 months ago |
| RSI: Overbought | Nov 5, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 8, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| RSI: Overbought | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 18, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 3, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 29, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 27, 2025 | 1 year ago |
| RSI: Overbought | Aug 13, 2025 | 1 year ago |
| SMA: Bullish | Aug 7, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 29, 2025 | 1 year ago |
| RSI: Oversold | Jul 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 25, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 6, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 22, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 8, 2025 | 1 year ago |
| RSI: Overbought | Dec 6, 2024 | 1 year ago |
| RSI: Overbought | Nov 25, 2024 | 1 year ago |
Key statistics
- Market cap
- 4.02B
- Enterprise value
- 3.75B
- Trailing P/E
- 35.72
- Forward P/E
- 25.74
- PEG ratio
- 0.00
- Price / sales
- 7.15
- Price / book
- 2.89
- EPS (TTM)
- 1.40
- Beta
- 1.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 20.37%
- Revenue (TTM)
- 561.90M
- Revenue growth
- 15.50%
- Free cash flow
- 106.23M
- Total cash
- 485.23M
- Total debt
- 40.11M
- Return on equity
- 8.77%
- Shares outstanding
- 80.39M
- Short % of float
- 14.44%
- 50-day average
- 44.26
- 200-day average
- 42.78
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 59.73 +19.4% upside
Now 50.01
- Target (low)
- 45.00
- Target (mean)
- 59.73
- Target (high)
- 70.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.40973.
Financials — quick view
VCYT Revenue — quarterly 150.32M
VCYT Net income — quarterly 25.49M
VCYT EPS — quarterly 0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.4103 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.4103 | 0.54 | +0.13 | +31.61% |
| May 5, 2026 | Mar 31, 2026 | 0.34 | 0.52 | +0.18 | +52.94% |
| Feb 25, 2026 | Dec 31, 2025 | 0.4083 | 0.53 | +0.12 | +29.81% |
| Nov 4, 2025 | Sep 30, 2025 | 0.32 | 0.51 | +0.19 | +59.38% |
| Aug 6, 2025 | Jun 30, 2025 | 0.31 | 0.44 | +0.13 | +41.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 9, 2026 | UBS | main | Buy | Buy |
| Aug 4, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 4, 2026 | Stephens & Co. | main | Overweight | Overweight |
| Aug 4, 2026 | Morgan Stanley | main | Underweight | Underweight |
| Aug 3, 2026 | Canaccord Genuity | main | Hold | Hold |
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- veracyte.com
News
- Veracyte to Participate in Upcoming Investor Conferences
- Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Artisan Mid Cap Fund Q3 2026 Portfolio Update
- Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
- Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
- Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?
- Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
- Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program
- Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
- Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
Your note
Sign in to keep a note on VCYT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARR ELIAV | Director | Stock Award(Grant) | Jun 10, 2026 | 56,461 |
| BHANJI MUNA | Director | Sale | Oct 18, 2026 | 40,854 |
| CHAMBERS REBECCA | Chief Financial Officer | Sale | Sep 3, 2026 | 166,025 |
| EPSTEIN ROBERT S | Director | Stock Award(Grant) | Jun 10, 2026 | 57,718 |
| FEBBO PHILLIP G | Officer | Sale | Sep 3, 2026 | 133,048 |
| HAAS KEVIN RICHARD | Officer | Stock Award(Grant) | Apr 9, 2026 | 44,221 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.78% | 13,486,437 | 674.46M | Jun 29, 2026 |
| FMR, LLC | 9.58% | 7,702,746 | 385.21M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 6.89% | 5,538,404 | 276.98M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.87% | 4,716,191 | 235.86M | Jun 29, 2026 |
| State Street Corporation | 5.84% | 4,698,128 | 234.95M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 3,593,922 | 179.73M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 4,787,107 | 239.40M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 2,532,110 | 126.63M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.90% | 2,332,081 | 116.63M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.60% | 2,092,968 | 104.67M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 1,830,642 | 91.55M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.07% | 1,666,407 | 83.34M | Sep 29, 2026 |